Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells. - Wikidata - awgldk - TriplyDB

Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.

Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.

http://www.wikidata.org/entity/Q39361715

about

Photodynamic tumor eradication with a novel targetable photosensitizer: strong vascular effects and dependence on treatment repetition versus potentiation.Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model.Lipid-based nanocarriers for breast cancer treatment - comprehensive review.EGF-liposomes promote efficient EGFR targeting in xenograft colocarcinoma model.The achievement of ligand-functionalized organic/polymeric nanoparticles for treating multidrug resistant cancer.Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy.Methotrexate-conjugated quantum dots: synthesis, characterisation and cytotoxicity in drug resistant cancer cells.Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives.Nanomedicine applications in the treatment of breast cancer: current state of the art.

P2860

Q34474855-3A9CC43D-8E75-4103-9594-DD17D7C70B85 Q36157045-D1CB1E4D-2830-407A-9F71-EAEEFA97B6E9 Q36412928-B66EF417-B40B-4AA7-BD0D-CCEF74902228 Q38597794-285FA814-9E86-463E-AFBD-44142CB5FDAB Q38792917-3EE31DF1-BF90-46E6-84CC-26146ED3919E Q38809044-997D99E6-B57A-4EB6-A93F-19722A0544E1 Q38850036-8638C420-059D-4A1E-BF9C-05CF4465BF3B Q38852895-EE24F1BB-D9B8-485C-8467-5775E0AFAF22 Q38854876-D5B1AF12-1EF2-42A8-9AF6-70BA6C6246E4 Q41483629-FBCCB46E-1308-42AD-90CB-885AE6013141

P2860

Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.

http://www.wikidata.org/entity/Q39361715

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Immunoliposomal delivery of do ...... FR-overexpressing tumor cells.

@en

Immunoliposomal delivery of do ...... FR-overexpressing tumor cells.

@nl

type

label

Immunoliposomal delivery of do ...... FR-overexpressing tumor cells.

@en

Immunoliposomal delivery of do ...... FR-overexpressing tumor cells.

@nl

prefLabel

Immunoliposomal delivery of do ...... FR-overexpressing tumor cells.

@en

Immunoliposomal delivery of do ...... FR-overexpressing tumor cells.

@nl

P1433

Q39361715-72C5BC74-864C-4E9A-8AB1-84A6D99E3F87

P1476

Q39361715-7A441889-45A6-475C-A64A-8F51A3E13756

P2093

Q39361715-0024DE27-0B78-4318-84EE-A0A32C39FDA0

Q39361715-02CA5712-5F70-455B-86F5-1756C1215550

Q39361715-74428F1D-1D17-4191-9215-305598DFE059

Q39361715-997640D3-372D-430B-8985-321E7C3ECDFF

Q39361715-EF50EF3E-9C51-46FC-AF9E-629FA6DD1365

P2860

Q39361715-07F947A9-08F1-4B22-A188-B0C2F00A4A6C

Q39361715-138454A0-B35E-4FD8-A4F4-6CB772D99F11

Q39361715-18D5741A-635A-479B-8989-27C6525CBEC2

Q39361715-1947D7A2-CE31-4C5E-BA4F-E3128D87BCDE

Q39361715-2FB143AF-345C-4316-8784-9F782D78316B

Q39361715-3EACB727-D8F5-44E9-B632-3CB1C663A731

Q39361715-4E54D527-3755-4624-9BEC-B49E84E66A2C

Q39361715-649B7843-425A-490C-9B2F-369F6095F5BE

Q39361715-68537D0A-4562-473C-B133-D1AABB5117CD

Q39361715-6E68FE3A-BF21-459B-B438-ECF3DA268CC9

P304

Q39361715-EB933970-0AC7-441C-8AFE-373C943E3A74

P31

Q39361715-664A9B47-D124-4A96-8E27-B4FC2C0C8149

P356

Q39361715-ACA69B98-7954-45C5-938E-072DE5D71CB2

P433

Q39361715-CDD7E6C5-07FC-4AC3-B0AD-33F8A65AF331

P478

Q39361715-B65C15BF-910E-47EF-B701-1CF677E78BF8

P50

Q39361715-7F7E6253-409F-46CC-949F-A4739AD7336F

Q39361715-D879A014-F172-4C1B-94ED-73989AF55680

P577

Q39361715-165308B8-667F-4E71-8B42-26DB587DAEE5

P698

Q39361715-F9405381-6C1F-44DB-98A4-34DB9A9F065A

P921

Q39361715-44466B8D-2BBA-4047-BD07-01C2D34EEF03

Q39361715-9DEAF709-BF41-4B14-BF1E-4490F47AE4BC

P356

1061186X.2012.680960

P1433

Journal of Drug Targeting

P1476

Immunoliposomal delivery of do ...... GFR-overexpressing tumor cells

@en

P2093

Christoph Rochlitz

http://www.w3.org/2001/XMLSchema#string

Jan Schuller

http://www.w3.org/2001/XMLSchema#string

Reto Ritschard

http://www.w3.org/2001/XMLSchema#string

Richard Herrmann

http://www.w3.org/2001/XMLSchema#string

Willy Küng

http://www.w3.org/2001/XMLSchema#string

P2860

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Pharmacological strategies for overcoming multidrug resistance.

The role of ABC transporters in clinical practice.

The (patho)physiological functions of the MRP family.

Development of anti-p185HER2 immunoliposomes for cancer therapy

Liposome-based approaches to overcome anticancer drug resistance.

Development of ligand-targeted liposomes for cancer therapy.

Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters.

Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.

EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.

P304

422-432

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/1061186X.2012.680960

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Christoph Mamot

P577

2012-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22519893

http://www.w3.org/2001/XMLSchema#string

P921

multiple drug resistance